We’ve rebranded some of our products, learn more ›

CODEX® is now PhenoCycler,
Phenoptics™ is now Phenolmager.

Category: Akoya Perspectives

How can we help progress promising cancer therapies to the clinic? Proteomics based companion diagnostic (CDx) tests are emerging as a critical success factor. Read more to learn how Acrivon Therapeutics and Akoya’s technologies are paving the way forward.